Literature DB >> 30803989

Fostamatinib for the treatment of chronic immune thrombocytopenia.

Nathan T Connell1,2, Nancy Berliner1,2.   

Abstract

Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib's mechanism of action and its clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.
© 2019 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30803989     DOI： 10.1182/blood-2018-11-852491

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  The NEK family of serine/threonine kinases as a biomarker for cancer.

Authors:  Nagesh Kishan Panchal; Sabina Evan Prince
Journal:  Clin Exp Med       Date:  2022-01-17       Impact factor: 3.984

Review 2.  Nanomedicines in B cell-targeting therapies.

Authors:  Jiawei Wang; Jiyuan Yang; Jindřich Kopeček
Journal:  Acta Biomater       Date:  2021-10-21       Impact factor: 8.947

Review 3.  Development of New Drugs for Autoimmune Hemolytic Anemia.

Authors:  Zhengrui Xiao; Irina Murakhovskaya
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

4.  High titers and low fucosylation of early human anti-SARS-CoV-2 IgG promote inflammation by alveolar macrophages.

Authors:  Willianne Hoepel; Hung-Jen Chen; Chiara E Geyer; Sona Allahverdiyeva; Xue D Manz; Steven W de Taeye; Jurjan Aman; Lynn Mes; Maurice Steenhuis; Guillermo R Griffith; Peter I Bonta; Philip J M Brouwer; Tom G Caniels; Karlijn van der Straten; Korneliusz Golebski; René E Jonkers; Mads D Larsen; Federica Linty; Jan Nouta; Cindy P A A van Roomen; Frank E H P van Baarle; Cornelis M van Drunen; Gertjan Wolbink; Alexander P J Vlaar; Godelieve J de Bree; Rogier W Sanders; Lisa Willemsen; Annette E Neele; Diederik van de Beek; Theo Rispens; Manfred Wuhrer; Harm Jan Bogaard; Marit J van Gils; Gestur Vidarsson; Menno de Winther; Jeroen den Dunnen
Journal:  Sci Transl Med       Date:  2021-05-11       Impact factor: 17.956

Review 5.  Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.

Authors:  Kata P Szilveszter; Tamás Németh; Attila Mócsai
Journal:  Front Immunol       Date:  2019-08-09       Impact factor: 7.561

6.  Integrative Multi-omics Landscape of Non-structural Protein 3 of Severe Acute Respiratory Syndrome Coronaviruses.

Authors:  Ruona Shi; Zhenhuan Feng; Xiaofei Zhang
Journal:  Genomics Proteomics Bioinformatics       Date:  2021-11-10       Impact factor: 6.409

7.  Characterizing the structure-activity relationships of natural products, tanshinones, reveals their mode of action in inhibiting spleen tyrosine kinase.

Authors:  Min-Che Tung; Keng-Chang Tsai; Kit-Man Fung; Ming-Jaw Don; Tien-Sheng Tseng
Journal:  RSC Adv       Date:  2021-01-14       Impact factor: 3.361

Review 8.  Targeting SARS-CoV-2-Platelet Interactions in COVID-19 and Vaccine-Related Thrombosis.

Authors:  Dermot Cox
Journal:  Front Pharmacol       Date:  2021-07-05       Impact factor: 5.810

9.  Lymphatic blood filling in CLEC-2-deficient mouse models.

Authors:  Elizabeth J Haining; Kate L Lowe; Surasak Wichaiyo; Raghu P Kataru; Zoltan Nagy; Dean Pj Kavanagh; Sian Lax; Ying Di; Bernhard Nieswandt; Benoît Ho-Tin-Noé; Babak J Mehrara; Yotis A Senis; Julie Rayes; Steve P Watson
Journal:  Platelets       Date:  2020-03-04       Impact factor: 3.862

10.  Sequence-specific 2'-O-methoxyethyl antisense oligonucleotides activate human platelets through glycoprotein VI, triggering formation of platelet-leukocyte aggregates.

Authors:  Martina H Lundberg Slingsby; Prakrith Vijey; I-Ting Tsai; Harvey Roweth; Genevieve Couldwell; Adrian R Wilkie; Hans Gaus; Jazana M Goolsby; Ross Okazaki; Brooke E Terkovich; John W Semple; Jonathan N Thon; Scott P Henry; Padmakumar Narayanan; Joseph E Italiano
Journal:  Haematologica       Date:  2022-02-01       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.